# TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

> **NCT02322281** · PHASE3 · TERMINATED · sponsor: **Clovis Oncology, Inc.** · enrollment: 149 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Rociletinib
- **DRUG:** Pemetrexed or gemcitabine or paclitaxel or docetaxel

## Key facts

- **NCT ID:** NCT02322281
- **Lead sponsor:** Clovis Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2018-03-29
- **Final completion:** 2018-03-29
- **Target enrollment:** 149 (ACTUAL)
- **Why stopped:** Sponsor discontinued development of CO-1686 for NSCLC
- **Last updated:** 2019-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02322281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02322281, "TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02322281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*